Andere Sprachen Interpace Biosciences, Inc.

Aktien

A2PYCU

US46062X3035

IDXG

Verzögert OTC Markets Andere Börsenplätze 21:53:39 09.05.2024			% 5 Tage	% 1. Jan.
1.4 ^USD	+2.34%		-0.71%	+29.63%

07.03.	Interpace Biosciences, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
07.03.	Interpace Biosciences, Inc. meldet Ergebnis für das vierte Quartal bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Interpace Biosciences Announces First Quarter 2024 Financial and Business Results	09.05.
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	07.03.
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results	07.03.
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07.03.
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee	12.12.
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director	16.11.
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08.11.
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results	08.11.
Interpace Biosciences, Inc. Enters Amendment to Loan Security Agreement with Broadoak Fund V, L.P	27.10.23
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results	09.08.23
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09.08.23
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer	02.08.23
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement	10.07.23
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023	05.06.23
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023	05.06.23
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12.05.23
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q1 Revenue $9.8M	12.05.23
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results	12.05.23
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Principal Financial Officer	25.04.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Interpace Biosciences, Inc.

Aktien

A2PYCU

US46062X3035

IDXG

Andere Sprachen

Filter